Clinical Trial: Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients

U.S., Jan. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07342803) titled 'Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma Patients' on Dec. 11, 2025.

Brief Summary: This is a multicenter, randomized, masked, active and placebo controlled, Phase II clinical study to evaluate the efficacy, safety, and pharmacokinetics of LP-003 injection in adult patients with moderate to severe persistent allergic asthma.

Study Start Date: Jan. 25, 2025

Study Type: INTERVENTIONAL

Condition: Allergic Asthma

Intervention: BIOLOGICAL: LP-003 Injection

s.c. injection, Q12W

BIOLOGICAL: Omalizumab

s.c. injection, Q4W

BIOLOGICAL: Placebo

s.c. injection, Q4W

Recruitment Status: RECRUITING...